June 2, 2015Open Access

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Key Points

Key points are not available for this paper at this time.

Abstract

At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Stefan Bielack

Sigbjørn Smeland

Jeremy Whelan

Journals

Journal of Clinical Oncology

Actions

Institutions

Memorial Sloan Kettering Cancer Center

WinnMed

Moffitt Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study